Turmeric compound tested to stall cancer in High-Risk patients
NCT ID NCT04731844
First seen May 13, 2026 · Last updated May 19, 2026 · Updated 2 times
Summary
This pilot study tested whether a daily supplement of curcumin (from turmeric) and piperine (from black pepper) could slow or stop disease progression in 30 patients with early-stage prostate cancer, MGUS, or low-risk smoldering multiple myeloma. Participants took the supplement twice a day for up to 12 months while staying on active surveillance. The goal was to see if the supplement could reduce cancer markers or prevent the disease from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Rochester
Rochester, New York, 14623, United States
Conditions
Explore the condition pages connected to this study.